---
title: "Germany's Merck KGaA Raises Outlook on Robust Results, Easing Currency Headwinds"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295059022.md"
description: "Germany's Merck KGaA raised its full-year guidance for the second consecutive quarter, citing robust performance and easing currency headwinds. The company now expects net sales of €21 billion to €21.8 billion with organic growth of 1% to 3%, up from previous forecasts. EBITDA excluding one-time items is projected at €5.9 billion to €6.3 billion. Management attributed the upgrade to abating foreign-exchange pressures, stronger demand in life-science and electronics markets, and resilience in healthcare operations."
datetime: "2026-08-06T05:31:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295059022.md)
  - [en](https://longbridge.com/en/news/295059022.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295059022.md)
generator: "portal-rs"
---

# Germany's Merck KGaA Raises Outlook on Robust Results, Easing Currency Headwinds

By Adria Calatayud

Germany's Merck KGaA raised its full-year guidance for the second quarter in a row, citing a robust performance and easing foreign-exchange headwinds. 

The German life-sciences and chemicals group said Thursday that it now expects net sales for the full year to range from 21 billion to 21.8 billion euros ($24.26 billion-$25.19 billion), with organic growth of 1% to 3%. It had previously forecast sale to be flat or grow up to 3% organically, resulting in revenue of 20.4 billion to 21.4 billion euros. 

The company anticipates earnings before interest, taxes, depreciation and amortization excluding one-time items to be between 5.9 billion and 6.3 billion euros, with growth of up to 3%. This compares with its previous guidance of 5.7 billion to 6.1 billion euros, with an organic performance ranging from a 2% fall to a 2% rise. 

Merck, which already lifted its full-year outlook alongside first-quarter results, said this reflected abating foreign-exchange headwinds and expectations of stronger demand in the life-science and electronics markets, together with resilience in its healthcare operations. 

"Our second-quarter performance confirms continued momentum from important growth drivers across all the industries we serve," Chief Executive Kai Beckmann said. 

Write to Adria Calatayud at adria.calatayud@wsj.com 

(END) Dow Jones Newswires

August 06, 2026 01:22 ET (05:22 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### Related Stocks

- [MKKGY.US](https://longbridge.com/en/quote/MKKGY.US.md)
- [MRK.DE](https://longbridge.com/en/quote/MRK.DE.md)

## Related News & Research

- [Germany’s Merck KGaA raises outlook on robust results, easing currency headwinds](https://longbridge.com/en/news/295061471.md)
- [Merck KGaA (0O14) Gets a Buy from UBS](https://longbridge.com/en/news/285522532.md)
- [EXL announces Departure of Vivek Jetley, President and Head of Insurance, Healthcare and Life Sciences | EXLS Stock News](https://longbridge.com/en/news/297794111.md)
- [09:01 ETHealthcare Is Moving Into the Home. Home Accessibility Now Has a Validated Score.](https://longbridge.com/en/news/297656740.md)
- [SoundHound AI (SOUN) On Healthcare Deal Momentum And The Case For A Higher Valuation](https://longbridge.com/en/news/297694466.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**